Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

- Phase 1b Combination Data Highlight Favorable Tolerability and Additive Antiviral Activity of HCV-796 -

EXTON, Pa., April 13, 2007 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced additional data from a Phase 1b study of HCV- 796, a unique, orally dosed hepatitis C virus (HCV) polymerase inhibitor at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). This meeting is being held in Barcelona, Spain. These data on the antiviral activity and tolerability of twice daily HCV-796 in combination with pegylated interferon alfa-2b (peg-IFN) elaborate on previously presented data. HCV-796 is currently undergoing Phase 2 evaluation and is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth .

These Phase 1b combination data demonstrate the additive antiviral effects of HCV-796 across multiple genotypes of hepatitis C virus, in treatment-naïve adult subjects with chronic hepatitis C infection. HCV-796 dosed twice daily plus peg-IFN displays clinical antiviral activity that is greater than that of HCV-796 or peg-IFN alone across all dose cohorts and tested HCV genotypes. Final safety and tolerability data show that HCV-796 is generally well tolerated when added to peg-IFN. Adverse events were generally consistent with known effects of interferons. No dose-limiting toxicities were observed across the range of HCV-796 study doses.

"In this Phase 1b study, HCV-796 provided added antiviral activity to that of pegylated interferon across multiple HCV genotypes and did so largely without altering interferon's tolerability profile," commented Colin Broom, ViroPharma's chief scientific officer. "The adverse events observed in patients on combination therapy were typical of those seen in patients on pegylated interferon alone. The antiviral activity of HCV-796, its strong tolerability profile, and its lack of dose limiting toxicities encou
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/17/2013)... 17, 2013  PENTAX Medical, a healthcare industry ... global leader in ultrasound imaging, recently announced renewed ... enable further innovation in the development of Endoscopic ... systems and PENTAX Medical endoscopic portfolio have formed ... EUS systems. This agreement will continue to grow ...
(Date:5/17/2013)... May 17, 2013 Oramed Pharmaceuticals ... oral drug delivery systems, announced today that the United ... Company,s Investigational New Drug application(IND) for ORMD-0801, its oral ... have the FDA clearance to proceed," stated ... trial is a major milestone for Oramed and we ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... Technology and Research (A*STAR) and Switzerland,s ... has been dosed in a Phase 1 clinical trial with ... Qbeta virus-like particle (VLP) technology. In this first Phase 1 ... candidate and its potential to protect against H1N1 influenza infection ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... 1, 2012 Anlit Advanced Nutrition Supplements ... dietary supplements for children, will present new and innovative products ... May 22-24, 2012 in Geneva, Switzerland. Anlit will ... Products Expo at Stand 3500. The company will present, ...
... SHENZHEN, China, April 30, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical ... developer, manufacturer and marketer of medical devices worldwide, announced ... Exchange Commission an Annual Report on Form 20-F that ... 31, 2011. An electronic version of Mindray,s Annual Report ...
Cached Medicine Technology:Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012 2Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) ... edition of what is considered the "bible" of modern ... continues. "This is unprecedented, the amount of commentary ... of the American Psychiatric Association (APA). "It,s been an ... You have to evaluate it and then make your ...
(Date:5/18/2013)... (May 18, 2013) The use of a ... colonoscopy, according to new research presented today at ... begins days in advance of the procedure, includes ... to be taken at strict intervals. The better ... to see cancer and precancerous polyps in the ...
(Date:5/18/2013)... 2013 Assisted living and retirement ... safety and comfort of their residents. Systems Technologies ... with an effective and cost-efficient solution – VisionLink ... integrated, turnkey communications solution that helps nurses provide ... independence and privacy. , The VisionLink ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The Communities ... the special places we call home. These are the townships, ... They are the locations where the people are friendly and ... takes viewers off the highways and shares the best in ... both nations with an American sports and film celebrity. It ...
(Date:5/18/2013)... TheBeautyPlace.com answers important questions about the hairloss ... a result of stress, nutrient deficiency or wearing a ... of men suffer from male patterned baldness. ... hair transplant surgery, but additionally carries a hair care ... Bosley Professional Strength. Their product line is a five-step ...
Breaking Medicine News(10 mins):Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:New smartphone application improves colonoscopy preparation 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3
... VanTine HealthDay Reporter , FRIDAY, Dec. 3 (HealthDay News) ... interview, attractive women may be at a disadvantage, a new study ... men were twice as likely to generate requests for an interview, ... up to 30 percent less likely to get a response, whether ...
... FRIDAY, Dec. 3 (HealthDay News) -- If the expression "out ... may be at risk of forgetting about the global AIDS ... coverage of HIV/AIDS fell more than 70 percent in developed ... that tracked coverage in 115 leading broadsheet newspapers in 41 ...
... a quarter of Americans live in rural areas, which consistently ... suburban areas. Among the complex causes for this disparity is ... and almost 4 out of 10 rural residents live ... Finding the time, transportation, and financial resources for travel to ...
... News) -- Young women with a menopause-like condition called ... new study suggests. Women with the condition, called ... hormones, develop hot flashes, typically become infertile and, in ... develop as early as the teens or 20s, according ...
... children born with a rare genetic disease, according to ... Advancement of Science. The research was led by ... at Iowa State University, in collaboration with Dr. Patricia ... the Iowa State College of Veterinary Medicine, the University ...
... Goodwin HealthDay Reporter , THURSDAY, Dec. 2 (HealthDay ... circuitry of brain connections may someday be used to diagnose ... Boston and the University of Utah used MRIs to analyze ... in 30 males aged 8 to 26 with high-functioning autism ...
Cached Medicine News:Health News:Good Looks May Help Land the Interview -- for Men 2Health News:Good Looks May Help Land the Interview -- for Men 3Health News:Dramatic Decline Seen in AIDS News Coverage 2Health News:ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA 2Health News:Depression Screening Urged for Young Women With Menopause-Like Symptoms 2Health News:New discovery prevents symptoms of rare genetic disorder 2Health News:Brain Scan Might Someday Spot Autism 2Health News:Brain Scan Might Someday Spot Autism 3
Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
... Instrument Set offers maximum distraction with minimal ... by the Tangent Posterior Impacted Instrument Set ... to reproduce the technique. Set offers 9 ... body distraction. A variety of sizes of ...
Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
Medicine Products: